CVI Holdings’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

CVI Holdings’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-292,563	Closed	-$2.95M	–	630
2022 Q4	$2.95M	Hold	292,563	–	–	0.38%	91
2022 Q3	$2.9M	Hold	292,563	–	–	0.22%	161
2022 Q2	$2.9M	Buy	292,563 +9,137	+3%	+$89.6K	0.21%	177
2022 Q1	$2.79M	Buy	283,426 +58,469	+26%	+$576K	0.18%	198
2021 Q4	$2.21M	Buy	224,957 +24,957	+12%	+$245K	0.15%	229
2021 Q3	$1.95M	Hold	200,000	–	–	0.12%	280
2021 Q2	$1.93M	Hold	200,000	–	–	0.13%	253
2021 Q1	$1.94M	Buy	+200,000	New	+$1.94M	0.13%	236

CVI Holdings's BIOT Position: Q1 2023 in Review

CVI Holdings sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 292,563 shares — an estimated $2.95M sold.

CVI Holdings first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $2.95M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

CVI Holdings reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
CVI Holdings sold 292,563 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $2.95M.
CVI Holdings first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
CVI Holdings's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.95M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.